Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Advancements in Therapy for Indolent Non-Hodgkin's Lymphomas


Description:
The purpose of this presentation is to discuss recently approved and Phase 3 investigational targeted agents (small molecule kinase inhibitors and monoclonal antibodies). Discussion will focus on where these agents are changing the standard treatment options for indolent NHL as well as side effect management. 
 
Objectives:
1. Describe the pathophysiology, classification, clinical features, and presentation of indolent NHL. 
2. Review Follicular Lymphoma International Prognostic Index model and approach to risk-adapted
    treatment. 
3. Analyze the efficacy and place within treatment algorithms for targeted therapies, and how they
   compare to historic treatment strategies.
4. Identify toxicities and management strategies associated with therapies for indolent NHL.
 
Activity Number:
0280-0000-16-083-H01-P                                         
 
This recorded activity is a based on a live program that was offered on October 14, 2016 in Burlington, MA. 
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Application Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the activity evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Discloures:
The presenter is Amy H. Seung, PharmD, BCOP; Physician Resource Management (PRM), Senior Director, Clinical Initiatives, Ann Arbor, MI
Dr. Seung does not have any relevant financial relationships with any commercial interests   

     
The reviewer is Steven L. D'Amato, RPh, BSPharm; Executive Director, New England Cancer Specialists; President of the Association of Community Cancer Centers; Clinical Associate Professor, Tufts University School of Medicine 
Mr. D'Amato does not have any relevant financial relationships with any commercial interests  
   
Support for This Activity:
This activity is supported by the Association of Community Cancer Centers (ACCC).
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

The purpose of this presentation is to discuss recently approved and Phase 3 investigational targeted agents (small molecule kinase inhibitors and monoclonal antibodies). Discussion will focus on where these agents are changing the standard treatment options for indolent NHL as well as side effect management. 
 

Objectives

  • Describe the pathophysiology, classification, clinical features, and presentation of indolent NHL.
  • Review Follicular Lymphoma International Prognostic Index model and approach to risk-adapted treatment.
  • Analyze the efficacy and place within treatment algorithms for targeted therapies, and how they compare to historic treatment strategies.
  • Identify toxicities and management strategies associated with therapies for indolent NHL.

Speaker(s)/Author(s)

Amy H. Seung, PharmD, BCOP picture

Amy H. Seung, PharmD, BCOP
Physician Resource Management, Senior Director, Clinical Initiatives, Ann Arbor, MI


Brief Bio : Amy Hatfield Seung, PharmD, BCOP, is the Senior Director of Clinical Initiatives Physician Resource Management (PRM). In this role, she leads user development and clinical content for the Caretâ„¢ platform. Previously, she was the Oncology Clinical Decision Support and Hematologic Malignancies Pharmacy Clinical Specialist at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital where she also served as Director of the PGY2 Oncology Pharmacy Residency Program. Dr. Seung received her Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill, and completed her Pharmacy Practice and Oncology Specialty Residencies at the University of Washington Medical Center and Seattle Cancer Care Alliance in Seattle, Washington. Dr. Seung serves as a lead consultant in the development of the National Comprehensive Cancer Network (NCCN) Standard Chemotherapy Templates and worked on the NCCN Task Force on Specialty Pharmacy. She is active within the Hematology Oncology Pharmacy Association (HOPA) and is Past Chair of the BCOP Recertification Committee and BCOP Field Testing Workgroup. Dr. Seung has authored multiple oncology articles and book chapters and spoken nationally on oncology medication and pharmacy topics.

Activity Number

0280-0000-16-083-H01-P

Release Date: Nov 21, 2016
Credit Expiration Date: Nov 21, 2018

CE Hours

1.00